Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
March 12, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
March 05, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Announces Reverse Stock Split
February 05, 2020 12:45 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for...
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
January 24, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1...
Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson
January 21, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD...
Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
January 16, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
December 11, 2019 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
November 08, 2019 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling...